Antitumor Activity of a Duocarmycin Analogue Rationalized to Be Metabolically Activated by Cytochrome P450 1A1 in Human Transitional Cell Carcinoma of the Bladder - Sutherland, Mark; Gill, Jason H.; Loadman, Paul M.; Laye, Jonathan P.; Sheldrake, Helen M.; Illingworth, Nicola A.; Alandas, Mohammed N.; Cooper, Patricia A.; Searcey, Mark; Pors, Klaus; Shnyder, Steve D.; Patterson, Laurence H. (Molecular cancer therapeutics, 2013)
Keywords: Animals; Antineoplastic Agents - metabolism; Antineoplastic Agents - pharmacokinetics; Antineoplastic Agents - pharmacology; Biotransformation; Carcinoma, Transitional Cell - drug therapy; Carcinoma, Transitional Cell - enzymology; Carcinoma, Transitional Cell - pathology; Cell Line, Tumor; Cell Survival - drug effects; CHO Cells; Cricetinae; Cytochrome P-450 CYP1A1 - genetics; Cytochrome P-450 CYP1A1 - metabolism; Female; Gene Expression; Humans; Indoles - metabolism; Indoles - pharmacokinetics; Indoles - pharmacology; Liver - metabolism; Maximum Tolerated Dose; Mice; Mice, Inbred BALB C; Microsomes, Liver - metabolism; Pyrroles - metabolism; Pyrroles - pharmacokinetics; Pyrroles - pharmacology; Tumor Burden - drug effects; Urinary Bladder Neoplasms - drug therapy; Urinary Bladder Neoplasms - enzymology; Urinary Bladder Neoplasms - pathology; Xenograft Model Antitumor Assays